---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Antidepressants and other psychiatric pharmacotherapy"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Antidepressants and other psychiatric pharmacotherapy. Topics: EHDN international guideline: depression, irritability, and anxiety; EHDN international guideline: suicide risk assessment; HDSA physician's guide: pharmacotherapy for depression; German Neurological Society guideline: psychiatric symptoms; 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/antidepressants-and-other-psychiatric-pharmacotherapy"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Antidepressants and other psychiatric pharmacotherapy

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Antidepressants and Other Psychiatric Pharmacotherapy

<a id="topic-2.2.2.1.3-1"></a>

### EHDN international guideline: depression, irritability, and anxiety

> “An antidepressant may be suggested if depression occurs in HD (Grade B)”
> “It is recommended to use a selective SSRI or a serotonin noradrenaline reuptake inhibitor (SNRI), or alternatively Mianserin or Mirtazapine, in case of sleep disruption.”
> “Whilst SSRIs are first lines for irritability (Grade C)”
> “SSRI or SNRI are first line treatments of anxiety, especially when associated with depression.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.3-2"></a>

### EHDN international guideline: suicide risk assessment

> “Suicide risk should be assessed in HD irrespective of the stage, being particularly vigilant at the time of diagnosis and when the disease starts to impact on day-to-day life.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.3-3"></a>

### HDSA physician's guide: pharmacotherapy for depression

> “There is no single preferred antidepressant for treating depression in HD.”

Source: [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf)

<a id="topic-2.2.2.1.3-4"></a>

### German Neurological Society guideline: psychiatric symptoms

> “There is hardly any data from RCTs or controlled studies on treating mental health problems in HD. Recommendations are therefore based on expert opinion.”

Source: [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)

<a id="topic-2.2.2.1.3-5"></a>

### Expert-based consensus guidelines on agitation, anxiety, apathy, psychosis, and sleep disorders

> “An international committee of 11 multidisciplinary experts proposed a series of statements regarding the description and management of each symptom.”
> “High-level agreement (≥85% experts strongly agreed or agreed) was reached for 107 of the 110 statements that have been incorporated into the expert-based clinical recommendations presented herein.”

Source: [Anderson et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6294590/)

<a id="topic-2.2.2.1.3-6"></a>

### Systematic review of pharmacological treatment of neuropsychiatric symptoms

> “Fifteen articles qualified for critical evaluation: 10 randomized controlled trials (RCTs) (five placebo-controlled and five cross-over) and five open label studies.”
> “As a result, convincing evidence that could guide clinical practice is lacking.”

Source: [Andriessen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11998698/)

<a id="topic-2.2.2.1.3-7"></a>

### MDS evidence-based review: psychiatric symptoms

> “There was no eligible evidence to support the use of specific treatments for depression, psychosis, irritability, apathy, or suicidality.”

Source: [Ferreira et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34842303/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
